Revenue Recognition (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Feb. 28, 2019	Mar. 31, 2021	Jun. 30, 2019	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Aug. 31, 2019
Revenue recognized				$ 17,800
Deferred revenue, Long-term				20,001	$ 21,318
Other assets				18,330	18,820
Deferred revenue				30,778	28,722	$ 72,930
Deferred revenue, current portion				10,777	7,404
Total revenues				820,222	625,486	391,005
Deferred revenue, long-term portion				20,001	21,318
Revenue recognized during the period that was included in deferred revenues at the beginning of the period				8,782	37,784
Product
Revenue recognized				7,400	5,700	5,400
Cost of revenues				453,632	315,195	200,097
Total revenues				797,307	580,080	377,877
Licensing and other
Cost of revenues				2,624	3,223	3,523
Total revenues				22,915	$ 45,406	$ 13,128
Genetic testing services
Revenue recognized				11,400
Deferred revenue, current portion				10,700
Revenue recognized during the period that was included in deferred revenues at the beginning of the period				3,300
Qiagen | Other licensing and other revenue
Refunds of revenues previously deferred		$ 10,000
Deferred revenue		$ 28,600
BGI Genomics
Revenue recognized				4,500
Proceeds from license agreement	$ 50,000		$ 35,600
Deferred revenue, Long-term				20,000
Prepaid expenses and other current assets				4,000
Deferred revenue, current portion				100
Deferred revenue, long-term portion				20,000
BGI Genomics | Sequencing services
Other assets			6,000
BGI Genomics | Sequencing products
Other assets			4,000
BGI Genomics | Sequencing products and services
Other assets			$ 10,000
Foundation Medicine ("FMI")
Revenue recognized				$ 16,800
Agreement term				5 years
Automatic renewals, successive period thereafter				1 year
Foundation Medicine ("FMI") | Upfront licensing fees and prepaid revenues
Initial transaction price							$ 13,300
Foundation Medicine ("FMI") | Developmental, regulatory, and commercial milestones
Initial transaction price							$ 32,000